This article is more than 5 years old. Information may no longer be current.

VIDEO: New primary endpoint for phase 3 trial of ANG-3777

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — At the National Kidney Foundation Spring Clinical Meetings, Tracy Mayne, PhD, vice president of medical affairs at Angion Biomedica, spoke about the mechanism of action for ANG-3777 and its phase 3 trial.

He said ANG-3777 is currently in phase 3 for the treatment of delayed graft function in patients with acute kidney injury associated with renal transplant. The phase 3 trial is similar to the phase 2 trials in that patients who have severe oliguria for the first 30 hours are randomized to ANG-3777 or placebo, he said. However, the primary endpoint has changed to the number of days on dialysis.

ANG-3777 is also in phase 2 for the treatment of cardiac surgery-associated AKI.